Evidence map›Paper›PMID 42327587›Full record

ArticleJournal of Cancer2026

CellVizio

Paul Zarogoulidis, Wolfgang Hofenforst-Schwidt, Haidong Huang, Stavros Tryfon, Yifei Zhang, Guoren Ma, Kyriakos Amarantidis, Elena Maragouli, Vasilis Papadopoulos, Eleni-Isidora Perdikouri and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Paul ZarogoulidisPulmonary-Oncology Department, General Clinic Imithea, Thessaloniki, Greece.
Wolfgang Hofenforst-SchwidtThorax Centre Südwestfalen, Märkische Kliniken, ''Lüdenscheid'' Clinics, aff. University of Bonn and Private University of Hamburg, Germany.
Haidong HuangDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Naval Medical University (Shanghai Changhai hospital), Shanghai, China.
Stavros TryfonPulmonary-Oncology Department, 'G.Papanikolaou' General Hospital, Thessaloniki, Greece.
Yifei ZhangDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Naval Medical University (Shanghai Changhai hospital), Shanghai, China.
Guoren MaThe Fourth People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, China.
Kyriakos AmarantidisOncology Department, General University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece.
Elena MaragouliOncology Department, General University Hospital of Thessaly, University of Thessaly, Larissa, Greece.
Vasilis PapadopoulosOncology Department, General University Hospital of Thessaly, University of Thessaly, Larissa, Greece.
Eleni-Isidora PerdikouriOncology Department, General Hospital of Volos, Volos, Greece.
Vagelis VoulgarisOncology Department, General Hospital of Volos, Volos, Greece.
Lutz FreitagDivision of Interventional Pneumology, Department of Pulmonary Medicine, University Hospital Essen - Ruhrlandklinik, Essen, Germany.
Chrysoula Margioula-SiarkouSecond Department of Obsetrics and Gynaecology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Theodora TsioudaPulmonary-Oncology Department, Theageneio Cancer Center, Thessaloniki, Greece.
Paschalis NtoliosInternal Medicine, Nursing School, Democritus University of Thrace, General University Hospital of Alexandroupolis, Thrace, Greece.
Stamatis PetousisSecond Department of Obsetrics and Gynaecology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Konstantina TriantafylopoulouThoracic Surgery Department, Interbalkan Medical Center, Thessaloniki, Greece.
Kosmas TsakiridisThoracic Surgery Department, Interbalkan Medical Center, Thessaloniki, Greece.
Nikolaos CourcoutsakisRadiology Department, General University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece.
Sofia BakaOncology Department, 'G. Papageorgiou' General University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Dimitris BaloukasOncology Department, 'G. Papageorgiou' General University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Paschalis SteiropoulosPulmonary Department, University General Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece.
Bojan ZaricFaculty of Medicine, University of Novi Sad, Institute for pulmonary diseases of Vojvodina, Serbia.
Xiaping ShenDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Naval Medical University (Shanghai Changhai hospital), Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The best tissue sample is still very important for the diagnosis of mesothorax lymphadenopathy. In the past 20 years endobronchial ultrasound (EBUS) has been used efficiently in most cases of primary lung cancer disease or metastatic disease. Several new type of needles have been created such 19G, 18G and hybrid biopsies with cryoprobes. Rapid on-site evaluation (ROSE) is used as an additional initial diagnostic tool. Confocal microscopy is a method of rapid on-site evaluation. Patients and Methods: One hundred patients with mesothorax lymphadenopathy were biopsied with ebus and two groups were created one with rapid on-site evaluation with confocal microscopy and one by an operator with microscopic evaluation with sample preparation on cytoglasses. Our main objective was to assess parameters such as time, false negative results between the two techniques and technical issues such as the accessibility and evaluation between the two techniques. Safety was also evaluated. Results: Rapid on-site evaluation is more cost efficient with a cytologist on site, however; with a higher rate of false negative results. Accessibility with the Cellvizio Discussion: Confocal is a safe and time-efficient technique for mesothorax lymphadenopathy. A high level of training is required for pulmonary physicians in order to assess the novel imaging technique. Definitely different parts of the lymphnode have to reached and evaluated in order to have a proper initial evaluation.

Indexed as

18G needlebronchoscopyCellvizio®confocal microscopyebusPentaxrose

Identifiers

PMID42327587
PMCPMC13280631

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.